AlphAIAlphAI — Financial news for AI agents
stocktitan.net$WW

Third-quarter results from Weight Watchers are due before markets open Nov. 5. The call is scheduled for 8:30 a.m.

Weight Watchers (WW) will release its Q3 2026 earnings before market open on Nov. 5, 2026, followed by a conference call at 8:30 a.m. ET. The webcast and replay will be available on the company's website. Weight Watchers is a global leader in weight management, offering science-backed programs and support.

Original reporting
stocktitan.net
Published Oct 26, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$WW
Neutral
medium confidence
Mentioned
$WW
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$WWNeutralLow
01

Why it matters

The earnings date announcement alone is unlikely to move the stock significantly; investors will react once the actual numbers are released.

02

Market read

The article serves as a reminder of the upcoming earnings release with no new financial metrics.

03

What to watch

Analysts may focus on upcoming GLP‑1 partnership announcements that could influence the earnings outcome.

Relevance 4/10Novelty 2/10Timing: pre‑market on Nov 5

Background

Weight Watchers is a publicly traded weight‑management company (Nasdaq: WW) that regularly reports quarterly results.

Company-level read

Ticker impact

$WWNeutralMedium confidence
Context

Weight Watchers (WW) announced its Q3 2026 earnings will be released before market open on Nov 5, 2026.

Expected impact

no immediate impact expected as the market awaits the actual results

Evidence & confidence

Date announcements typically have limited price effect until the earnings numbers are disclosed.

Market effects

Sector

None beyond the health‑and‑wellness sector awaiting the earnings report.

Regional

Limited to U.S. investors tracking the stock.

Global

Low; the news is company‑specific.

Counterpoint

What could challenge this read

Some traders may view the lack of detail as a chance to short ahead of a potentially disappointing earnings beat.

Key entities

  • company
    Weight Watchers International, Inc.

    Provider of weight‑management programs and services.

Read at source← All news

Related articles

$WWMedAI 8/10

What WW International (WW) Said on Its Q3 Earnings Call

WW International reported Q3 earnings, highlighting a 40% YoY increase in clinical subscribers to 174,000, though down from 197,000 in Q2. Behavioral subscription revenue fell 22% to $113.9M, while clinical revenue rose 48% to $38M. Adjusted gross margin reached 74.6%, and marketing expenses declined. The company narrowed its 2026 revenue guidance to $625M-$630M and adjusted EBITDA to $110M-$115M. Cash increased to $126.4M, and debt was reduced by 70%.

finance.yahoo.com
$WWMedAI 8/10

WW International Inc (WW) (Q3 2026) Earnings Call Highlights: Clinical Revenue Surges 48%

WW International reported Q3 2026 revenue of $152.9M, down 11% YoY, with behavioral subscription revenue dropping 22%. Clinical revenue surged 48%, but clinical subscribers declined sequentially. Full-year revenue guidance was narrowed to $625-$630M. Core+ subscribers grew 16% YoY, driven by GLP-1 program adoption and virtual experiences. The company expects flat gross margins at ~74% despite clinical mix growth.

finance.yahoo.com
$WWMed

WW International, Inc. Q3 2026 Earnings Call Summary

WW International reported Q3 2026 earnings, highlighting a strategic shift to higher-value tiers (Core+ and Med+) generating 50% of revenue. Clinical revenue grew 48% YoY, driven by Med+ and GLP-1 Success Program. Core+ saw subscriber growth for four consecutive quarters. The company expects sustainable growth in 2027, with clinical revenues projected to reach 25% of total revenue. Debt reduced by 70% since 2025, and net income turned positive.

finance.yahoo.com